AstraZeneca

21,833

$54.35
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.13 (-2.05%) Today
+$0.48 (+0.89%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell AstraZeneca and other stocks, options, ETFs, and crypto commission-free!

About AZN

AstraZeneca PLC, also called AstraZeneca, is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. Read More The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Employees
70,600
Headquarters
Cambridge, Cambridgeshire
Founded
1992
Market Cap
141.38B
Price-Earnings Ratio
106.76
Dividend Yield
2.49
Average Volume
7.52M
High Today
$55.27
Low Today
$53.76
Open Price
$54.60
Volume
4.48M
52 Week High
$57.44
52 Week Low
$36.15

Collections

AZN News

Reuters4h

Morning News Call - India, June 5

June 5 (Reuters) - To access a PDF version of this newsletter, please click here here If you would like to receive this newsletter via email, please register at
30
BBC5h

Coronavirus vaccine: AstraZeneca boosts potential supply to 2bn

AstraZeneca said it will be able to supply two billion doses of a potential virus vaccine following two new deals. Last month, AstraZeneca said it could manufa
64
CNBC9h

AstraZeneca is aiming to produce 2 billion doses of a coronavirus vaccine — and it could be ready by September

Pharmaceutical company AstraZeneca is aiming to produce 2 billion doses of a coronavirus vaccine, including 400 million for the U.S. and U.K. and 1 billion for
1,267

AZN Earnings

$0.00
$0.53
$1.05
$1.58
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Estimated
per share
Actual
Available Jul 30, Pre-Market

You May Also Like

More AZN News

MarketWatch10h

AstraZeneca signs more virus vaccine supply deals

AstraZeneca PLC said Thursday it signed new agreements aimed at broadening global distribution of a coronavirus vaccine being developed by Oxford University res
52
Reuters13h

AstraZeneca targets two billion doses, poor countries with COVID vaccine deals

(Reuters) - British drugmaker AstraZeneca has doubled manufacturing capacity for its potential coronavirus vaccine to 2 billion doses in a handful of deals invo
30
New York Times14h

AstraZeneca Says Open for More Vaccine Production Deals

FRANKFURT — Britain's AstraZeneca will continue to look for more production partners for the experimental vaccine it is working on with Oxford University but it
2
The Economist17h

Schumpeter - The quest for a vaccine could restore faith in big pharma

U NPRECEDENTED IS AN overused word. But to find a parallel for the response of the pharmaceutical industry to the covid-19 pandemic, it is necessary to go back
53
Financial PostJun 3

Trump admin selects 5 coronavirus vaccine candidates as finalists - NYT

The Trump administration has selected five companies, including Moderna Inc, AstraZeneca Plc and Pfizer Inc, as the most likely candidates to produce a vaccine
514
ReutersJun 3

Brazil to start testing Oxford vaccine against the coronavirus this month

SAO PAULO (Reuters) - Brazil this month will start testing an experimental vaccine against the novel coronavirus being developed by researchers at the Universit
108
ReutersJun 1

AstraZeneca scores twin drug approvals alongside vaccine progress

(Reuters) - Britain’s AstraZeneca has clinched expanded regulatory backing for two medications, including one for blockbuster cancer treatment Lynparza, in a de
273
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.